← boardnext 2026-12next 2028-02
NXTC
NextCure, Inc.distress 9/10 · high distress / dilution risk$4.56+4%today-68% from 52w high
Oncology 2
Lead: ovarian · target PD-1 · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$15M
Runway
0.3 yrs
Shares 1y
+35%
Price & events
-64.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.6%
1D
-26.1%
1W
+151.9%
1M
-63.2%
3M
-61.7%
6M
-12.3%
1Y
-76.3%
2Y
-94.6%
5Y
-96.5%
All
Overview
- Market Cap
- $16.47M
- Volume
- 47.72K
- 52 Week Range
- $1.60 – $14.27
- Total Shares
- 3.61M
- Float Shares
- 2.26M
- Short %
- 4.39%
- % Held by Insiders
- 14.80%
- % Held by Institutions
- 62.40%
- RVOL
- 0.01x
- Beta
- 1.42
Pipeline stages · 4 programs
LNCB74
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SIM0505 for injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NC410, pembrolizumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NC525
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | LNCB74 | Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors | — | recruiting |
| 2028-02 Estimated 50% readout ~2028-03-02 | Phase 1 | SIM0505 for injection | Advanced Solid Tumors | — | recruiting |
| 2025-07 | Phase 1/2 | NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | active not recruiting |
| 2025-01-31 | Phase 1 | NC525 | Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome | 28 | terminated |
Catalyst news & presentations · 10
- second half of 2026Guided 55%readoutPhase 1LNCB74 · trial progress update instead of proof-of-concept data due to delaySEC 8-K
- 1H 2026readoutPhase 1LNCB74 · Proof-of-concept data readout from Phase 1 dose escalation and expansionSEC 8-K
- Q2 2026conferencedata presentationsecondaryPhase 1SIM0505 · Phase 1 dose escalation data including patients from U.S. and ChinaSEC 8-K
- 2026-01-23enrollment delayLNCB74 · Proof-of-concept data delayed to accommodate enrollment; update now expected in H2 2026SEC 8-K
- Q4 2025readoutPhase 1LNCB74 · Proof of concept expectedSEC 8-K
- third quarter of 2025trial initiationsecondaryPhase 1SIM0505 · U.S. Phase 1 clinical trial expected to beginSEC 8-K
- 2025-06-13partnershipSIM0505 · Exclusive worldwide license (ex-China) for SIM0505 ADC from Simcere ZaimingSEC 8-K
- Q1 2025trial initiationsecondaryPhase 1LNCB74 · First-in-human trial initiationSEC 8-K
- Q4 2024regulatory submissionFiled (NDA/BLA)LNCB74 · IND submission for B7-H4 ADC LNCB74SEC 8-K
- 2024-12-10fda agreementLNCB74 · FDA accepted IND application for Phase 1 trial of LNCB74, a B7-H4-targeting ADC for multiple cancers.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $20 (+339% upside) · 3 analysts
- 2026-05-11LUCID CAPITAL MARKETSBuy
- 2025-11-07Ladenburg ThalmannNeutral → Buy
- 2025-07-15Piper SandlerOverweight
- 2025-07-01HC Wainwright & Co.Buy
- 2025-03-17HC Wainwright & Co.Buy
- 2025-03-07HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-21Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? - TradingView
- 2026-07-21Monteverde & Associates launches legal inquiries into mergers of VEEE, NXTC, TCBX, and FHB. - Pluang
- 2026-07-21NextCure announces reverse merger with privately held Avere - MSN
- 2026-07-21Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders - GlobeNewswire
- 2026-07-21Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders - GlobeNewswire
- 2026-07-17NextCure Inc. (NXTC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
- 2026-07-17NextCure Inc. (NXTC) Faces Continued Pressure, Testing Key Support Levels - Gap Fill Strategy - dars.gov.et
- 2026-07-17NextCure and Avere Therapeutics Announce Merger and $320 Million Private Financing - Global Legal Chronicle
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.